ANAPTYSBIO INC SEC Filings

Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.

ANAPTYSBIO director Owen Hughes received a grant of restricted stock units (RSUs). On May 11, 2026, he was awarded 11,250 RSUs, each representing a contingent right to receive one share of common stock for no cash payment upon settlement.

One third of these RSUs will vest on May 11, 2027, with the remaining two thirds vesting in equal annual installments, provided he continues to serve the company on each vesting date. After this grant, his reported RSU holdings from this award total 11,250 units held directly.

ANAPTYSBIO, INC director Hughes Owen filed an initial insider ownership report on Form 3. This filing establishes his status as a company insider under SEC rules. The submission does not list any buy, sell, or other reportable transactions and shows no derivative positions.

ANAPTYSBIO, INC director Hughes Owen filed an initial insider ownership report on Form 3. This filing establishes his status as a company insider under SEC rules. The submission does not list any buy, sell, or other reportable transactions and shows no derivative positions.

Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.

The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.

Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.

The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.

ANAPTYSBIO, INC executive Christopher M. Murphy, the company’s Chief Financial Officer, has filed an initial Form 3 reporting his beneficial ownership status. In this filing, he does not report any transactions or existing holdings, indicating no reportable equity position or activity at the time of this statement.

ANAPTYSBIO, INC executive Christopher M. Murphy, the company’s Chief Financial Officer, has filed an initial Form 3 reporting his beneficial ownership status. In this filing, he does not report any transactions or existing holdings, indicating no reportable equity position or activity at the time of this statement.

AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.

If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.

AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.

If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.

AnaptysBio, Inc. filed Amendment No. 1 to its annual report to add detailed disclosures on directors, executive officers, governance, compensation and ownership, instead of using a separate proxy statement. The filing updates board class composition following director departures so that six directors are evenly split across three staggered classes, and confirms committee memberships and independence.

The amendment describes 2025 non‑employee director compensation, including cash retainers and equity grants, and outlines a pay‑for‑performance program for executives that combines salary, annual bonuses and stock‑based incentives such as options, RSUs and performance stock units tied to ambitious share‑price hurdles. It also explains severance and change‑in‑control protections, a clawback policy, and the impact of the April 2026 spin‑off of First Tracks Biotherapeutics, including the CEO’s consulting arrangement and equity award treatment.

AnaptysBio, Inc. filed Amendment No. 1 to its annual report to add detailed disclosures on directors, executive officers, governance, compensation and ownership, instead of using a separate proxy statement. The filing updates board class composition following director departures so that six directors are evenly split across three staggered classes, and confirms committee memberships and independence.

The amendment describes 2025 non‑employee director compensation, including cash retainers and equity grants, and outlines a pay‑for‑performance program for executives that combines salary, annual bonuses and stock‑based incentives such as options, RSUs and performance stock units tied to ambitious share‑price hurdles. It also explains severance and change‑in‑control protections, a clawback policy, and the impact of the April 2026 spin‑off of First Tracks Biotherapeutics, including the CEO’s consulting arrangement and equity award treatment.

AnaptysBio, Inc. completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, Inc. on April 20, 2026 and is now providing unaudited pro forma financial information reflecting the company after this separation.

The pro forma balance sheet as of December 31, 2025 shows a $100.0 million initial cash distribution to First Tracks, reducing AnaptysBio’s cash and cash equivalents from $238,196 to $138,196 (in thousands). Pro forma 2025 results convert a historical net loss of $13,232 (in thousands) into net income of $114,857 (in thousands), with collaboration revenue of $234,603 (in thousands) and basic pro forma earnings per share of $3.99.

Notes explain that First Tracks is treated as discontinued operations under ASC 205, that AnaptysBio anticipates approximately $7.0 million of additional non-recurring spin-off costs, and that a transition services agreement will add about $2.0 million to general and administrative expenses.

AnaptysBio, Inc. completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, Inc. on April 20, 2026 and is now providing unaudited pro forma financial information reflecting the company after this separation.

The pro forma balance sheet as of December 31, 2025 shows a $100.0 million initial cash distribution to First Tracks, reducing AnaptysBio’s cash and cash equivalents from $238,196 to $138,196 (in thousands). Pro forma 2025 results convert a historical net loss of $13,232 (in thousands) into net income of $114,857 (in thousands), with collaboration revenue of $234,603 (in thousands) and basic pro forma earnings per share of $3.99.

Notes explain that First Tracks is treated as discontinued operations under ASC 205, that AnaptysBio anticipates approximately $7.0 million of additional non-recurring spin-off costs, and that a transition services agreement will add about $2.0 million to general and administrative expenses.

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.

ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.

Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.

ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.

Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.

AnaptysBio director John P. Schmid reported multiple stock option adjustments tied to a corporate separation. On the reported date, he received several option grants to buy AnaptysBio common stock and simultaneously disposed of corresponding options back to the issuer.

A footnote explains that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into an option for First Tracks shares and an option for AnaptysBio shares. As a result, Schmid acquired new AnaptysBio options in amounts determined under that agreement. One referenced stock option is fully vested and exercisable, while another vests in 1/12 monthly installments starting on February 6, 2026, contingent on his continued service.

AnaptysBio director John P. Schmid reported multiple stock option adjustments tied to a corporate separation. On the reported date, he received several option grants to buy AnaptysBio common stock and simultaneously disposed of corresponding options back to the issuer.

A footnote explains that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into an option for First Tracks shares and an option for AnaptysBio shares. As a result, Schmid acquired new AnaptysBio options in amounts determined under that agreement. One referenced stock option is fully vested and exercisable, while another vests in 1/12 monthly installments starting on February 6, 2026, contingent on his continued service.